Lamour Nadia F, Chalfant Charles E
Department of Biochemistry, Virginia Commonwealth University School of Medicine and Massey Cancer Center, Richmond, VA 23298, USA.
Mol Interv. 2005 Dec;5(6):358-67. doi: 10.1124/mi.5.6.8.
It has been over a decade since ceramide kinase (CERK) and its product, ceramide-1-phosphate (C1P), were first reported. Since itscloning, in 2002, CERK has been the subject of an explosion of publications concerning various signal transduction pathways. The roles of this previously overlooked enzyme, as well as those of its product C1P, continue to expand, and their regulatory functions in the production of eicosanoid inflammatory mediators are proving essential to fundamental signal transduction pathways. In particular, C1P is required for the activation and translocation of cPLA(2)alpha, the initial rate-limiting step of eicosanoid synthesis. The potential for inhibitors of CERK to offer a new generation of anti-inflammatory and anti-cancer therapeutics is especially deserving of further study.
自神经酰胺激酶（CERK）及其产物神经酰胺-1-磷酸（C1P）首次被报道以来，已经过去了十多年。自2002年克隆以来，CERK一直是大量有关各种信号转导途径的出版物的主题。这种先前被忽视的酶及其产物C1P的作用不断扩大，并且它们在类花生酸炎症介质产生中的调节功能对于基本信号转导途径至关重要。特别是，C1P是cPLA(2)α激活和易位所必需的，而cPLA(2)α是类花生酸合成的初始限速步骤。CERK抑制剂提供新一代抗炎和抗癌疗法的潜力尤其值得进一步研究。
